Co-Diagnostics, Inc. CODX
0.36 USD -0.02 (-4.89%)
At closeNov 5, 2026, 4:20 AM EST
0.38 +0.02 +6.25%
Pre-market · Nov 5, 4:20 AM ET
0.355 Day range 0.3913
0.35 52-week range 13.54
- YTD
- -92.87%
- 1 year
- -96.93%
News
prnewswire.com Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of…
benzinga.com Co-Diagnostics Announces Publication Of Peer-Reviewed Study Using SARAGENE Human Papillomavirus High Risk Test Manufactured By CoSara Diagnostics Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology ResultsCoSara to Exhibit at MICROCON 2026,…
prnewswire.com Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology Results CoSara to Exhibit at MICROCON 2026,…
benzinga.com Co-Diagnostics Moves Closer to Commercial Tuberculosis Test Launch in India Co-Diagnostics filed for Indian clearance for its rapid TB test following successful trials, targeting commercial sales before the year-end.
benzinga.com Co-Diagnostics's India JV CoSara Diagnostics Completes Its Clinical Performance Study Of The CoSara PCR Mycobacterium Tuberculosis Test On CoSara PCR Pro Instrument; Has Submitted Test To India's Central Drugs Standard Control Organization For Regulatory Clearance The submission follows the Company's July 22, 2026 announcement that CoSara had initiated clinical studies for the CoSara PCR MTB test across select laboratories in India. The clinical study assessed…
benzinga.com Co-Diagnostics To Demonstrate Co-Dx PCR Platform, MTB Test At WHX Labs Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its